Document:

Exhibit 10.64

 

AMENDMENT NO. 1 TO

AMYLIN PHARMACEUTICALS, INC.

CHANGE IN CONTROL EMPLOYEE

SEVERANCE BENEFIT PLAN

 

The Amylin Pharmaceuticals, Inc. Change in
Control Employee Severance Benefit Plan (the “Plan”) is hereby amended as
follows, effective as of September 17, 2003:

 

1.                                      The
last sentence of Section 1 of the Plan is hereby amended and restated in
its entirety to be as follows:

 

“The Plan was approved by the Compensation Committee
of the Board of Directors of the Company effective February 8, 2001, and
amended by the Board of Directors of the Company effective September 17,
2003.”

 

2.                                      Clause
(ii) in Section 2(d) of the Plan, which is part of the Plan’s definition
of “Change in Control,” is hereby amended and restated in its entirety to be as
follows:

 

“(ii) there is consummated a sale or other
disposition of all or substantially all of the assets of the Company (other
than a sale to an entity where at least 50% of the combined voting power of the
voting securities of such entity are owned by the stockholders of the Company
in substantially the same proportions as their ownership of the Company
immediately prior to such sale);”

 

3.                                      Section 7
of the Plan is hereby amended and restated in its entirety to be as follows:

 

“SECTION 7.  CLAIMS, INQUIRIES AND APPEALS

 

(a)                                  Applications
for Benefits and Inquiries.  Any
application for benefits, inquiries about the Plan or inquiries about present
or future rights under the Plan must be submitted to the Plan Administrator in
writing by an applicant (or his or her authorized representative).  The Plan Administrator is:

 

Amylin Pharmaceuticals, Inc.

9360 Towne Centre Drive

San Diego, California 92121

 

(b)                                  Denial
of Claims.  In the event that any
application for benefits is denied in whole or in part, the Plan Administrator
must provide the applicant with written or electronic notice of the denial of
the application, and of the applicant’s right to review the denial.  Any electronic notice will comply with the
regulations of the U.S. Department of Labor. 
The written notice of denial will be set forth in a manner designed to
be understood by the employee and will include the following:

 

1

 

(i)                                    the specific reason
or reasons for the denial;

 

(ii)                                references to the
specific Plan provisions upon which the denial is based;

 

(iii)                            a description of any
additional information or material that the Plan Administrator needs to
complete the review and an explanation of why such information or material is
necessary; and

 

(iv)                               an explanation of the
Plan’s review procedures and the time limits applicable to such procedures,
including a statement of the applicant’s right to bring a civil action under
section 502(a) of ERISA following a denial on review of the claim, as
described in Section 7(d) below.

 

This written
notice will be given to the applicant within ninety (90) days after the Plan
Administrator receives the application, unless special circumstances require an
extension of time, in which case, the Plan Administrator has up to an additional
ninety (90) days for processing the application.  If an extension of time for processing is required, written
notice of the extension will be furnished to the applicant before the end of
the initial ninety (90) day period.

 

This notice of
extension will describe the special circumstances necessitating the additional
time and the date by which the Plan Administrator is to render its decision on
the application.

 

(c)                                  Request
for a Review.  Any person (or that
person’s authorized representative) for whom an application for benefits is
denied, in whole or in part, may appeal the denial by submitting a request for
a review to the Plan’s Review Panel within sixty (60) days after the
application is denied.  The Review Panel
shall be comprised of two (2) or more persons to be appointed by the
Company.  A request for a review shall
be in writing and shall be addressed to:

 

Review Panel

Change in Control Employee Severance Benefit Plan

Amylin Pharmaceuticals, Inc.

9360 Towne Centre Drive

San Diego, California 92121

 

A request for
review must set forth all of the grounds on which it is based, all facts in
support of the request and any other matters that the applicant feels are
pertinent.  The applicant (or his or her
representative) shall have the opportunity to submit (or the Review Panel may
require the applicant to submit) written comments, documents, records, and
other information relating to his or her claim.  The applicant (or his or her representative) shall be provided,
upon request and free of charge, reasonable access to, and copies of, all
documents, records and other information relevant to his or her claim.  The review shall take into account all
comments, documents, records and other information submitted by the applicant
(or his or her representative) relating to the claim, without regard to

 

2

whether such information
was submitted or considered in the initial benefit determination.

 

(d)                                  Decision
on Review.  The Review Panel will
act on each request for review within sixty (60) days after receipt of the
request, unless special circumstances require an extension of time (not to
exceed an additional sixty (60) days), for processing the request for a
review.  If an extension for review is
required, written notice of the extension will be furnished to the applicant
within the initial sixty (60) day period. 
This notice of extension will describe the special circumstances
necessitating the additional time and the date by which the Plan Administrator
is to render its decision on the review. 
The Review Panel will give prompt, written or electronic notice of its
decision to the applicant. Any electronic notice will comply with the
regulations of the U.S. Department of Labor. 
In the event that the Review Panel confirms the denial of the
application for benefits in whole or in part, the notice will set forth, in a
manner calculated to be understood by the applicant, the following:

 

(i)                                    the
specific reason or reasons for the denial;

 

(ii)                                references
to the specific Plan provisions upon which the denial is based;

 

(iii)                            a
statement that the applicant is entitled to receive, upon request and free of
charge, reasonable access to, and copies of, all documents, records and other
information relevant to his or her claim; and

 

(iv)                               a
statement of the applicant’s right to bring a civil action under
section 502(a) of ERISA.

 

(e)                                  Rules
and Procedures.  The Plan
Administrator and/or the Review Panel may establish rules and procedures,
consistent with the Plan and with ERISA, as necessary and appropriate in
carrying out its responsibilities in reviewing benefit claims.  The Review Panel may require an applicant
who wishes to submit additional information in connection with an appeal from the
denial of benefits to do so at the applicant’s own expense.

 

(f)                                    Exhaustion
of Remedies.  No legal action for
benefits under the Plan may be brought until the claimant (i) has submitted a
written application for benefits in accordance with the procedures described by
Section 7(a) above, (ii) has been notified by the Plan Administrator that
the application is denied, (iii) has filed a written request for a review of
the application in accordance with the appeal procedure described in
Section 7(c) above, and (iv) has been notified in writing that the Plan
Administrator has denied the appeal. 
Notwithstanding the foregoing, if the Plan Administrator and/or Review
Panel, as the case may be, does not respond to a Participant’s claim or appeal
within the relevant time limits specified in this Section 7, the
Participant may bring legal action for benefits under the Plan pursuant to
Section 502(a) of ERISA.”

 

3

 

4.                                      Section 10
of the Plan is hereby amended and restated in its entirety to be as follows:

 

“The Company reserves the right to amend or terminate
this Plan at any time; provided, however,
that this Plan may not be amended or terminated within 90 days prior to or at
any time following the occurrence of a Change in Control.  In the event that the Company has not
terminated this Plan prior to December 31, 2003, this Plan shall
thereafter remain in effect for successive two-year periods beginning
January 1, 2004 until the Board elects that the then-current two-year
period shall be the final effective period for this Plan by a duly adopted
resolution effected at least 90 days prior to the expiration of that two-year
period; provided,
however, that no such election shall be given any effect in the
event that a Change in Control has occurred or occurs prior to the expiration
of that two-year period.”

 

5.                                      The
sentence following the caption “Agent for the Service of Legal Process” in
Section 14 of the Plan is hereby amended and restated to be as follows:

 

“The Plan’s agent for service of legal process
is:  General Counsel, Amylin
Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121.”

 

4Exhibit 10.1

 

EMPLOYMENT AGREEMENT

 

This Employment Agreement, effective as of the 16th day of
September, 2003 (the “Effective Date”), is made by and between RadView
Software, Inc., a New Jersey corporation (“RadView”) and Christopher Dineen
(“Employee”).

 

WHEREAS RadView is a wholly owned subsidiary of RadView Software Ltd.,
an Israeli corporation (“Parent”);

 

WHEREAS Employee and RadView have entered into an agreement which
includes among other things, a covenant not to compete with RadView by the
Employee, a non-solicitation agreement and an assignment of inventions
agreement; and

 

WHEREAS Employee and RadView desire to set forth additional terms of
Employee’s employment;

 

NOW, THEREFORE, the parties hereto agree as follows:

 

1.   
Definitions.

 

For purposes of this Agreement:

 

a.               “Accrued Obligations” shall mean all
amounts of Annual Compensation due and owing, reimbursements properly submitted
for expenses incurred prior to the termination date and any accrued but unused
vacation owed to the Employee as of the termination date.

 

b.              “Cause” shall mean any act of or omission
by Employee in the conduct of Employee’s duties and responsibilities that
constitutes gross negligence or willful misconduct, or any act of or omission
by Employee that involves dishonesty or criminal conduct.  In the event the Board of Directors of
RadView (the “Board”) determines it has reason to terminate Employee’s
employment for Cause, it shall give written notice to Employee stating the specific
grounds constituting Cause.  In the event
that the Cause alleged constitutes any act or omission in the conduct of
Employee’s duties and responsibilities which constitutes gross negligence or
willful misconduct, Employee shall have an opportunity within five (5) days
after receiving such notice to meet with the Board to discuss such allegations
of Cause.

 

c.               “Change of Control”
shall mean:  (i) any sale, lease,
exchange or other transfer (in one transaction or a series of transactions) of
all or substantially all of the assets of RadView or Parent; (ii) individuals
who, as of the date hereof, constitute the entire Board of Directors of RadView
or of Parent (the “Incumbent Directors”) cease for any reason to constitute at
least a majority of the Board of Directors of such company, provided that any
individual becoming a director subsequent to the date hereof whose election was
approved by a vote of at least a majority of the then Incumbent Directors shall
be, for the purposes of this provision, considered as though such individual
were an Incumbent Director; (iii) any consolidation or merger of RadView or
Parent with any other entity where the shareholders of RadView or Parent
immediately prior to the consolidation or merger, would not, immediately after
the consolidation or merger, beneficially own, directly or indirectly, shares
representing fifty percent (50%) of the combined voting power of all of the
outstanding securities of the entity issuing cash or securities in the
consolidation or merger (or its ultimate parent corporation, if any); (iv) a
third person, including a “person” as defined in Section 13(d)(3) of the
Exchange Act, becomes the beneficial owner (as defined in Rule 13d-3
under the Exchange Act) directly or indirectly, of securities of RadView or of
Parent representing fifty percent (50%) or more of the total number of votes
that may be cast for the election of the directors of RadView; or (vi) the
Board of Directors of RadView or Parent, by vote of a majority of all the
Directors, adopts a resolution to the effect that a “Change-in-Control” has
occurred for purposes of this Agreement.

 

d.              “Good Reason” means that (i) Employee’s
compensation has been materially reduced (and such reduction is not part of an
overall reduction in compensation affecting other Employees of RadView), (ii)
Employee’s position, duties or responsibilities have been materially reduced,
(iii) the Employee’s primary place of employment is

 

 

moved to a location greater than sixty (60) miles away from its then
current location, or (iv) RadView has not paid to Employee when due any
undisputed compensation, including salary or bonus, and in all such cases
(i-iv) the condition continues beyond 15 business days from the date RadView’s
Board is notified in writing of its existence. 
Notwithstanding anything contained herein to the contrary, a material
reduction in Employee’s position, duties or responsibilities shall be deemed to
have occurred if, for example and without in anyway limiting the foregoing, a
Change of Control resulting in RadView or Parent becoming a subsidiary of
another entity occurs and Employee’s position, duties or responsibilities are
not otherwise reduced (unless Employee is also awarded identical or superior
position, duties and responsibilities with any such parent entity).

 

2.  Change of Control.

 

Upon a Change of Control, 50% of all unvested
stock options and/or restricted shares held by Employee shall immediately vest.

 

3. 
Termination of Employment Subsequent to a Change of Control.

 

a.               If, within 12 months of a Change of
Control (i) Employee terminates his employment with Good Reason or (ii)
Employee’s employment is terminated without Cause, then, in either case,
Employee will receive on his termination date the Accrued Obligations and
severance pay equal to six (6) months of his annual base salary then in effect
payable in equal installments (minus applicable withholdings) over a
six-(6)-month period following such termination;

 

b.              Employee shall
continue to receive the same health benefits as he was receiving prior to such
termination for six (6) months following such termination; and

 

c.               All remaining
unvested stock options and/or restricted shares shall immediately vest.

 

4. 
Termination of Employment Absent a Change of Control.

 

a.               If, absent a Change of Control within
the preceding twelve (12) months, (i) Employee terminates his employment with
Good Reason or (ii) Employee’s employment is terminated without Cause, then, in
either case, Employee will receive (i) on his termination date the Accrued
Obligations and (ii) severance pay equal to three (3) months of his annual base
salary then in effect payable in equal monthly installments (minus applicable
withholdings) following such termination;

 

b.              Employee shall
continue to receive the same health benefits as he was receiving prior to such
termination for three (3) months following such termination.

 

5.              Governing
Law; Arbitration; Injunctive and Other Relief

 

This Agreement shall be governed by and construed and enforced in
accordance with the laws of the Commonwealth of Massachusetts applicable to
agreements made and to be performed entirely in Massachusetts (without regard
to its conflict of laws statutes).  Each
party hereby irrevocably consents to the exclusive jurisdiction of the federal
and state courts located in Massachusetts with respect to any actions that may
arise in connection with this Agreement and are not required by this Section 5
to be arbitrated.  Except as provided in
this Section 5, any controversy or claim arising out of or relating to this
Agreement, or the breach thereof, shall be settled by arbitration administered
by the American Arbitration Association in accordance with its Commercial
Arbitration Rules, and judgment on the award rendered by the arbitrators may be
entered in any court having jurisdiction thereof.

 

Each of the parties to this Agreement acknowledges that a breach of
this Agreement may cause the other party irreparable harm that may not be
adequately compensated by money damages. 
Therefore, in the event of a breach or threatened breach by a party,
injunctive or other equitable relief will be available to the other party, and
any arbitrator acting pursuant to this Agreement shall have the authority to
provide such injunctive or other equitable relief.  Remedies provided herein are not exclusive.

 

2

 

The arbitrator shall have the authority to award such remedies or
relief that a court of the Commonwealth of Massachusetts could order or grant
in an action governed by Massachusetts law, including, without limitation,
specific performance of any obligation created under this Agreement, the
issuance of an injunction, or the imposition of sanctions for abuse or
frustration of the arbitration process. 
The arbitration proceedings shall be conducted in Boston, Massachusetts.

 

Notwithstanding the foregoing, any party may bring and pursue an action
in any federal or state court located in Massachusetts seeking provisional
relief, including a temporary restraining order or preliminary injunction,
pending an arbitration proceeding.  Any
provisional relief obtained shall be discontinued once the arbitrator has
assumed jurisdiction and ordered such discontinuance.

 

6.              Miscellaneous

 

a.               Survival.  Notwithstanding anything in this Agreement
to the contrary, Section 5 shall survive any termination of this Agreement.

 

b.              Successors and Assigns. The
provisions hereof shall inure to the benefit of, and be binding upon, the
successors, assigns, heirs, executors and administrators of the parties hereto.

 

c.               Entire Agreement; Amendment.  This Agreement constitutes the full and
entire understanding and agreement between the parties with regard to the
subjects hereto and thereof.  None of
this Agreement or any term hereof may be amended, waived, discharged or
terminated, except by a written instrument signed by both of the parties
hereto.

 

d.              Notices, etc.  All notices and other communications
required or permitted hereunder shall be in writing and shall be mailed by
certified or registered mail, postage prepaid, delivered either by hand or by
messenger, or transmitted by electronic telecopy (fax) addressed:

 

	
  If to RadView:

  
	
   

  	
  Ilan Kinreich

  
	
   

  	
  RadView Software, Inc.

  
	
   

  	
  7 New England Executive Park

  
	
   

  	
  Burlington, MA  01803

  
	
   

  	
   

  
	
  If to Employee, at:

  
	
   

  	
  Christopher Dineen

  

 

or at such other address as any party shall have furnished to the
others in writing.  All such notices and
other written communications shall be effective (i) if mailed, seven (7) days
after mailing (if mailed from outside the United States, such mailing must be
by airmail and said seven (7) days shall be fourteen (14) days),  (ii) if delivered, upon delivery, or  (iii) if faxed, one (1) business day after
transmission and acknowledgement of receipt by telephone or fax.

 

e.               Delays or Omissions.  No delay or omission to exercise any right,
power or remedy accruing to either party hereto upon any breach or default of
the other party under this Agreement shall impair any such right, power or
remedy of such party nor shall it be construed to be a waiver of any such
breach or default, or an acquiescence therein, or any similar breach or default
thereafter occurring.  No waiver of any
single breach or default shall be deemed a waiver of any other breach or
default theretofore or thereafter occurring. 
Any waiver, permit, consent or approval of any kind or character on the
part of any party hereto of any breach or default under this Agreement or any
waiver on the part of any party hereto of any provisions or conditions of this
Agreement must be made in writing and shall be effective only to the extent
specifically set forth in such writing. 
All remedies, either under this Agreement or by law or otherwise
afforded to any party, shall be cumulative and not alternative.

 

3

 

f.                 Separability.  In case any provision of this Agreement
shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or
impaired thereby.

 

g.              Prior Agreements.  In the event of conflict between the terms
of this Employment Agreement and any prior written or oral agreements related
to Employee’s employment with RadView, the terms of this Employment Agreement
shall prevail.

 

IN WITNESS WHEREOF, each of the parties has executed this Agreement as
of the Effective Date.

 

	
  Employee:

  	
   

  	
  RADVIEW SOFTWARE, INC.

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  /s/ CHRISTOPHER DINEEN

  	
   

  	
   

  	
  /s/  ILAN KINREICH

  	
   

  
	
  Name: Christopher Dineen

  	
   

  	
  By:  Ilan Kinreich

  	
   

  
	
   

  	
   

  	
  Name: Chief Executive Officer

  	
   

  
					

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}]]